OptimizeRx Corporation
HealthcareNASDAQ:OPRX · NASDAQ Capital Market
-$0.05 today
Vol 0.15M · Avg 0.49M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.0%
avg -9.7%
ROIC
5.6%
avg -8.7%
ROA
2.9%
avg -6.8%
Analysis
ROIC is currently the strongest return metric at 5.6% versus its period average of -8.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stephen L. Silvestro | Chief Executive Officer & Director | $1.13M | — | 48 | $185,288.00 | 0.99% |
Edward Stelmakh | Chief Financial & Strategic Officer | $937,673.00 | — | 60 | $123,172.00 | 0.66% |
Theresa Greco | Chief Commercial Officer | $781,771.00 | — | 53 | $71,954.00 | 0.38% |
Marion Odence-Ford | Chief Legal & Administrative Officer | $428,117.00 | — | 61 | $91,936.00 | 0.49% |
Sheryl Kearney | Human Resources Manager | — | — | — | — | — |
Maira Alejandra | Media Relations Manager | — | — | — | — | — |
Doug Besch | Chief Product Officer & Chief Technology Officer | — | — | 44 | $66,876.00 | 0.36% |
Andrew Jacob D'Silva | Chief Business Officer | — | — | 40 | $44,735.00 | 0.24% |
Heather Favazza | Controller | — | — | — | — | — |
Brendan Merrell | Chief Operating Officer | — | — | 41 | $26,207.00 | 0.14% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$243,615.68
Net Sentiment
$243,615.68
Net selling
Most Active
Stelmakh Edward
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $243,615.68 over the last 12 months. That adds up to net selling of $243,615.68. Stelmakh Edward was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +52.2% | +25.3% (12yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +52.2% over three years. Forward estimates point to Revenue at +25.3% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Bright Minds Biosciences Inc.
NASDAQ:DRUG
$473.06M
National Research Corporation
NASDAQ:NRC
$423.46M
TruBridge, Inc.
NASDAQ:TBRG
$391.78M
SOPHiA GENETICS S.A.
NASDAQ:SOPH
$349.74M
Simulations Plus, Inc.
NASDAQ:SLP
$329.75M
Semler Scientific, Inc.
SMLR
$310.75M
Spok Holdings, Inc.
NASDAQ:SPOK
$227.67M
RxSight, Inc.
NASDAQ:RXST
$194.98M
Definitive Healthcare Corp.
NASDAQ:DH
$88.59M
Nakamoto Inc.
NASDAQ:NAKA
$75.18M
Who manages OPRX?
OptimizeRx Corporation (OPRX) lists 10 active executives. The top listed executive is Sheryl Kearney, Human Resources Manager.
Are OPRX insiders buying or selling?
Recent insider activity shows net buying of $7.84M.
Explore More
Continue the stock analysis
Jump to another research area for this company.